Rani Therapeutics (RANI) Q4 2024 earnings summary

Executive summary

• Advanced RaniPill platform for oral biologics, demonstrating bioavailability comparable to subcutaneous injections across multiple indications, with a focus on obesity and immunology.

• Delivered preclinical data showing oral delivery of GLP-1/GLP-2 dual agonist (RT-114) and semaglutide via RaniPill capsule with bioequivalence to subcutaneous administration.

• Announced positive topline results from Phase 1 study of oral anti-IL-12/23 antibody (RT-111) with high bioavailability and good tolerability.

• Strategic partnership with ProGen for RT-114, targeting a differentiated obesity therapy.

• Completed two equity offerings raising $20.0 million in gross proceeds.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $27.6 million as of December 31, 2024, down from $48.5 million at year-end 2023.

• Contract revenue for 2024 was $1 million, with no contract revenue in 2023.

• Research and development expenses for 2024 were $26.7 million, down from $39.6 million in 2023, reflecting cost containment and workforce reduction.

• General and administrative expenses for 2024 were $23.9 million, down from $26.5 million in 2023.

• Net loss for 2024 was $56.6 million, improved from $67.9 million in 2023.

Outlook and guidance

• Cash runway expected to fund operations into Q3 2025 without additional funding.

• RT-114 clinical trial initiation planned for mid-2025, with a focus on obese, non-diabetic patients in phase I.

• Subsequent phase II-A study anticipated, testing multiple doses versus placebo.

• Continued prioritization of RT-114 due to capital constraints; other programs to advance as funding allows.